Toward Carbon Monoxide-Based Therapeutics: Critical Drug Delivery and Developability Issues

J Pharm Sci. 2016 Feb;105(2):406-416. doi: 10.1016/j.xphs.2015.10.018. Epub 2016 Jan 6.

Abstract

Carbon monoxide (CO) is an intrinsic signaling molecule with importance on par with that of nitric oxide. During the past decade, pharmacologic studies have amply demonstrated the therapeutic potential of carbon monoxide. However, such studies were mostly based on CO inhalation and metal-based CO-releasing molecules. The field is now at the stage that a major effort is needed to develop pharmaceutically acceptable forms of CO for delivery via various routes such as oral, injection, infusion, or topical applications. This review examines the state of the art, discusses the existing hurdles to overcome, and proposes developmental strategies necessary to address remaining drug delivery issues.

Keywords: CO-RMs; carbon monoxide; enzyme activated; metal free; photosensitive; targeted delivery.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Administration, Inhalation
  • Animals
  • Carbon Monoxide / administration & dosage*
  • Carbon Monoxide / chemistry*
  • Carbon Monoxide / pharmacokinetics
  • Drug Delivery Systems / methods*
  • Drug Delivery Systems / trends
  • Drug Discovery / methods*
  • Drug Discovery / trends
  • Humans
  • Prodrugs / administration & dosage
  • Prodrugs / chemistry
  • Prodrugs / pharmacokinetics

Substances

  • Prodrugs
  • Carbon Monoxide